Saturday, August 20, 2022 8:26:52 PM
UPDATE – Boon Industries Chairman Letter – $25M Projection with DiOx+ Sales Underway
Jan 14, 2021
BACK
SACRAMENTO, CA, Jan. 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BOON Industries (OTC PINK:BNOW) (“BOON” or the “Company”), announces the Chairman Letter.
Justin Gonzalez, Chairman and CEO, stated “The Company has completed its testing and compliance for its new product DiOx+. The Company has also received an EPA establishment number for the production of DiOx+. There are several immediate purchase orders from commercial buyers, and various GSA contractors evaluating the product for military, civilian and government applications.
“Our auditing firm is finalizing the Form-10 and the company anticipates being a fully-reporting issuer this quarter, along with up-listing to the OTCQB. This will change the dynamics of institutional investor opportunities for our market, and strengthen our trading analytics.
“The DiOx+ technology benefits i) the Agriculture & Food Processing sector for use as an anti-microbial pesticide, sanitizer and/or disinfectant for fruits and vegetables, and meat processing, ii) the Consumer Packaged Goods sector will utilize the product as a more cost effective oxidizing agent to disinfect and sanitize, iii) Commercial Logistics for use to reduce operational costs using DiOx+ to sanitize and disinfect warehousing and distribution centers, iv) the GSA/Health Services will use DiOx+ for a more effective solution to sanitizing and disinfecting applications, especially for Covid and other viral strains in medical facilities.
“The company has completed Phase I & II of building its production plant and corporate offices in Grass Valley, California, and has started production, bottling, labeling and shipping of its DiOx+ product. Projections during the next 3 years are approximately $25M.
“We look forward to a productive and exciting 2021, and welcome our shareholders to visit our facility and engage in supporting Boon Industries.”
Recent CSTF News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 02:52:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 03:40:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 05:24:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/08/2023 09:50:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:17:49 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 06:04:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM